2031 notes, 2029 notes, 2027 notes, and term loan, net-Term Loan
-
-
-
0
Deferred royalty obligations, net
884,053
879,374
871,185
855,030
Operating lease liabilities, net of current portion
14,645
14,973
14,216
3,811
Deferred revenue, net of current portion
8,968
10,424
11,776
13,080
Other long-term liabilities
1,405
240
229
244
Total liabilities
3,815,291
3,723,192
3,639,856
3,012,606
Redeemable convertible noncontrolling interests
-1,363
-1,018
-951
-570
Undesignated preferred stock and series a preferred stock-Undesignated Preferred Stock
0
-
-
-
Undesignated preferred stock and series a preferred stock-Series ACumulative Convertible Participating Preferred Stock
942,478
-
-
-
Common stock, 0.001 par value 500,000,000 shares authorized 198,759,831 shares issued and 192,633,286 shares outstanding as of june 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of december 31, 2025
207
206
204
202
Treasury stock, at cost 7,597,172 shares as of june 30, 2026 7,597,172 shares as of december 31, 2025
580,775
533,279
405,776
323,276
Additional paid-in capital
2,170,006
2,155,318
2,112,454
2,057,646
Accumulated other comprehensive income (loss)
-95
-7
-8
12
Accumulated deficit
-4,194,163
-4,137,453
-3,985,237
-3,821,194
Total bridgebio stockholders deficit
-1,662,342
-2,515,215
-2,278,363
-2,086,610
Noncontrolling interests
10,200
10,340
10,439
10,599
Total stockholders deficit
-1,652,142
-2,504,875
-2,267,924
-2,076,011
Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit
2,161,786
1,217,299
1,370,981
936,025
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.